Table 4.
Study population (N = 48,212) | ||
Variable | Hazards ratio | p-value |
Age | 0.989 | <.0001* |
Female | 1.048 | 0.0002* |
RxRisk categoriesa | ||
Anxiety and Tension, Bipolar Disorder, Depression, Psychotic Illness, ADD | 1.079 | <.0001* |
Asthma, Allergic Rhinitis | 1.031 | 0.1891 |
Cardiac Disease, Coronary & Peripheral Vascular Disease, Heart Disease, Hypertensionb | 0.973 | 0.2432 |
Gastric acid disorder, IBS | 1.004 | 0.8477 |
Rheumatoid Arthritis, Gout | 1.147 | <.0001* |
Thyroid Disease | 0.951 | 0.0426* |
Diabetes | 1.158 | <.0001* |
Business Type | ||
HMO | N/A | N/A |
Medicaid | 1.339 | <.0001* |
Medicare | 1.451 | <.0001* |
Self | 1.056 | 0.0013* |
Concomitant Other CVD-related Medications Used | ||
Digitalis | 1.138 | 0.0086* |
Nitrates | 1.224 | <.0001* |
Antiplatelet Medications | 1.097 | 0.0502 |
Antihyperlipidemic Medications | 0.797 | <.0001* |
Average copayc | 1.001 | 0.3831 |
Target medication classesd | ||
ARB/HCTZ | 0.529 | <.0001* |
ACEI/HCTZ | 0.536 | <.0001* |
BB/HCTZ | 0.532 | <.0001* |
* Significant p-value
a RxRisk categories shown in this table include the 7 most frequent disease states in the study cohort. All RxRisk disease categories were included in the model.
b This RxRisk category does not include the target medications, digitalis, nitrates, antiplatelet medications or antihyperlipidemics.
c Limited to HTN medications of the same class as the index drug.
d Reference Medication Class = HCTZ